Sign in Subscribe

Tempus AI - $TEM - Earnings Analysis: Strong revenue growth in both Genomics and Data and Services segments.

By sagebytes in Technology —

Business Model

Tempus AI generates revenue primarily through Genomics (diagnostic testing) and Data (licensing & analytical tools) with a growing contribution from Applications (therapy/trial matching & algorithmic diagnostics).

Revenue Sources

  • Genomics: Diagnostic testing services provide revenue from running tests and billing insurance or direct payment.
  • Data: Licensing de-identified multimodal records and software tools (Lens platform) to pharmaceutical and biotechnology companies.
  • Applications: Development of algorithmic diagnostics such as clinical trial matching and care gap closure, including AI-enabled “Intelligent Diagnostic” applications.

Income Statement Analysis

  • Revenue increased 35.8% year-over-year, driven by growth in both Genomics and Data and Services.
  • Gross profit increased 49.7%, outpacing revenue growth, led by the Data and Services segment.
  • Net loss improved significantly compared to the previous year, but still negative. Includes a significant amount of stock-based compensation.
  • Adjusted EBITDA also improved, moving closer to breakeven.

Balance Sheet Analysis

  • Cash and cash equivalents increased significantly, reflecting proceeds from the IPO. The initial public offering.
  • Total assets increased substantially, driven by the increased cash position and investment in joint venture.
  • Stockholders' equity improved from a deficit to positive equity, due to the IPO and accumulated other comprehensive income. Stockholders equity improved by $1,438,502,000.

Cash Flow Analysis

  • Net cash used in operating activities decreased slightly, reflecting improving operational efficiency.The net cash used in operating activities decreased by $25,294,000
  • Net cash used in investing activities increased due to investment in joint venture.Net cash used in investing activities increased by $90,079,000
  • Net cash provided by financing activities increased substantially due to issuance of common stock in connection with IPO. Net cash provided by financing activities increased by $376,782,000
  • Cash position significantly improved, driven by financing activities, particularly the IPO

Capital Allocation

The company is focused on expanding its genomics and data businesses, along with developing its AI applications platform. Capital is being deployed for acquisitions (Ambry Genetics), research and development, and to support the growth of its connected network of healthcare institutions.

Management Commentary

Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year.

We believe our investments in AI have positioned us well for the future, as technologies that seemed unimaginable a few short years ago increasingly allow us to make our diagnostics intelligent, helping patients live longer and healthier lives.

We remain on track to achieve our key financial milestones, with expected robust revenue growth and positive Adjusted EBITDA in 2025.

Overall Sentiment: Positive. Management is optimistic about future growth driven by Genomics, Data and Services, and AI-enabled diagnostics, with a focus on achieving profitability.

Disclaimer: This report is for informational purposes only and not investment advice. The analysis is based on limited information and subject to change. Investing in securities involves risks, including potential loss of principal. Past performance doesn't guarantee future results. Always conduct your own research, understand the risks, and consult a financial professional before making investment decisions.